Citi Appointed Depositary Bank for Burning Rock Biotech Limited’s Sponsored ADR Program
Citis Issuer Services, acting through Citibank, N.A., has been appointed by Burning Rock Biotech Limited (Burning Rock Biotech), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, as the depositary bank for its American Depositary Receipt (ADR) program.
- Citis Issuer Services, acting through Citibank, N.A., has been appointed by Burning Rock Biotech Limited (Burning Rock Biotech), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, as the depositary bank for its American Depositary Receipt (ADR) program.
- Each ADR represents one Class A ordinary share of Burning Rock Biotech.
- As a single-listed ADR program, the underlying Class A ordinary shares are not listed or publicly traded in the issuers home market.
- Citi is committed to providing Burning Rock Biotech and its investors with the highest quality ADR services, and our selection as depositary bank for the companys ADR program underscores the depth and breadth of Citis cross-border capabilities, said Dirk Jones, Head of Global Issuer Services at Citi.